Table 3.
Response evaluation criteria in solid tumors responses to conventional chemotherapy in patients with advanced solitary fibrous tumors (n = 25)*
|
Chemotherapy |
Response to chemotherapy n (%) |
|
|---|---|---|
| Stable disease | Progressive disease | |
| First-line therapy (n = 18) |
16 (89%) |
2 (11%) |
| All doxorubicin-based therapies |
14 |
1 |
| Doxorubicin + ifosfamide |
11 |
1 |
| Doxorubicin + dacarbazine |
1 |
0 |
| Doxorubicin + cisplatin |
1 |
0 |
| Doxorubicin |
1 |
0 |
| All gemcitabine-based therapies |
1 |
1 |
| Gemcitabine + docetaxel |
0 |
1 |
| Gemcitabine |
1 |
0 |
| Paclitaxel |
1 |
0 |
| Second-line therapy (n = 6) |
4 (67%) |
2 (33%) |
| Gemcitabine |
1 |
1 |
| Paclitaxel |
3 |
1 |
| Third-line therapy (n = 1) |
0 (0%) |
1 (100%) |
| Gemcitabine |
0 |
1 |
| All lines of therapy (n = 25) | 20 (80%) | 5 (20%) |
*Four patients were treated with 2 different regimens of chemotherapy, resulting in a total of 25 treatments.